For breast cancer prognosis, immunoglobulinkappa chain surfaces to the top

Clinical Cancer Research

Volumn 18, Issue 9, 2012, Pages 2417-2419

  Whiteside, Theresa L ^a   Ferrone, Soldano ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; RITUXIMAB; TRASTUZUMAB; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL INFILTRATION; CELLULAR IMMUNITY; DISEASE ASSOCIATION; GENE EXPRESSION; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN GENE; IMMUNOGLOBULIN KAPPA CHAIN GENE; INTRACELLULAR SIGNALING; METASTASIS FREE SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE;

BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOGLOBULINS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860499083     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0566     Document Type: Article

References (12)

1. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappaCas acompatible prognostic marker in human solid tumors. Clin Cancer Res 2012;18:2695-704.
2. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to antiepidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643-8. (Pubitemid 46548951)
3. Ito T, Saga S, Nagayoshi S, Imai M, Aoyama A, Yokoi T, et al. Class distribution of immunoglobulin-containing plasma cells in the stroma of medullary carcinoma of breast. Breast Cancer Res Treat 1986;7:97-103. (Pubitemid 16096175)
4. Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, et al. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 2002;169:1829-36. (Pubitemid 34857644)
5. Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, Pilch H, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008;68:5405-13.
6. Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltratingBcell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci U S A 2001;98:12659-64. (Pubitemid 33020002)
7. Mauerer R, Gruber R. Monoclonal antibodies for the immunotherapy of solid tumours. Curr Pharm Biotechnol. 2012 Feb 14. Epub ahead of print.
8. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce- Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4. (Pubitemid 44498003)
9. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011;29:610-8.
10. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 2011;132:545-53.
11. Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012;10:1-4.
12. Jensen-Jarolim E, Singer J. Cancer vaccines inducing antibody production: more pros than cons. Expert Rev Vaccines 2011;10:1281-9.